|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
To shine more light on the relationship between nanoparticle structure and cell uptake, we have designed several micelles based on fructose containing block copolymers, which are selective to GLUT5 receptors found on breast cancer cell lines.
|
30550258 |
2019 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
GLUT5 (fructose) and GLUT2 (glucose/fructose) might provide alternative targets for BC imaging as to why effects of hypoxia on GLUT1/2/5 levels and function were examined in human BC models.
|
29913554 |
2018 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
Fluorescent analogs of fructose target the fructose-specific transporter GLUT5 in breast cancers and have limited to no response from normal cells.
|
29642606 |
2018 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
Fructose-specific facilitative hexose transporter GLUT5 represents an alternative biomarker for PET imaging of hexose metabolism in BC.
|
29142019 |
2018 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
The high affinity of GLUT5 transporter for d-fructose in breast cancer cells has been discussed intensely.
|
28371343 |
2017 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
Taken together these results are consistent with GLUT 5 not being essential for fructose uptake in breast cancer cells and tissues.
|
22073218 |
2011 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
Expression analysis of GLUT isoforms was performed on two GLUT5 expressing breast cancer cell lines using western blotting and immunocytochemistry.
|
19586773 |
2009 |
|
Malignant neoplasm of breast
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
In situ RT-PCR and ultrastructural immunohistochemistry confirmed GLUT5 expression in breast cancer.
|
16523487 |
2006 |
|
Malignant neoplasm of breast
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Therefore, it is of clinical interest to investigate whether AS against Glut5 mRNA can tackle breast cancer.
|
15449313 |
2004 |
|
Malignant neoplasm of breast
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Therefore, it is of clinical interest to investigate whether AS against Glut5 mRNA can tackle breast cancer.
|
15449313 |
2004 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
To shine more light on the relationship between nanoparticle structure and cell uptake, we have designed several micelles based on fructose containing block copolymers, which are selective to GLUT5 receptors found on breast cancer cell lines.
|
30550258 |
2019 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
GLUT5 (fructose) and GLUT2 (glucose/fructose) might provide alternative targets for BC imaging as to why effects of hypoxia on GLUT1/2/5 levels and function were examined in human BC models.
|
29913554 |
2018 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Fructose-specific facilitative hexose transporter GLUT5 represents an alternative biomarker for PET imaging of hexose metabolism in BC.
|
29142019 |
2018 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
The high affinity of GLUT5 transporter for d-fructose in breast cancer cells has been discussed intensely.
|
28371343 |
2017 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Taken together these results are consistent with GLUT 5 not being essential for fructose uptake in breast cancer cells and tissues.
|
22073218 |
2011 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Expression analysis of GLUT isoforms was performed on two GLUT5 expressing breast cancer cell lines using western blotting and immunocytochemistry.
|
19586773 |
2009 |
|
Breast Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
In situ RT-PCR and ultrastructural immunohistochemistry confirmed GLUT5 expression in breast cancer.
|
16523487 |
2006 |
|
Breast Carcinoma
|
0.380 |
Therapeutic
|
disease |
CTD_human |
Therefore, it is of clinical interest to investigate whether AS against Glut5 mRNA can tackle breast cancer.
|
15449313 |
2004 |
|
Breast Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Therefore, it is of clinical interest to investigate whether AS against Glut5 mRNA can tackle breast cancer.
|
15449313 |
2004 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
BEFREE |
Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues.
|
16523487 |
2006 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
BEFREE |
The results imply an alternative way in treating breast tumor as the AS against Glut5, unlike tamoxifen, takes effect on breast tumor cells via suppressing the expression of Glut5 that they specifically possess, and regardless whether the breast tumors are estrogen dependent or not.
|
15449313 |
2004 |
|
Mammary Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
The results imply an alternative way in treating breast tumor as the AS against Glut5, unlike tamoxifen, takes effect on breast tumor cells via suppressing the expression of Glut5 that they specifically possess, and regardless whether the breast tumors are estrogen dependent or not.
|
15449313 |
2004 |
|
Mammary Neoplasms, Human
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5.
|
15449313 |
2004 |
|
Mammary Carcinoma, Human
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5.
|
15449313 |
2004 |
|
High density lipoprotein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |